Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Nuo Therapeutics, Inc. reported revenue of $3M, up 142.7% year over year. Operating margin was -76.0% and net margin -75.8%, on a free-cash-flow margin of -34.4% with capital expenditure at 8.3% of revenue. Every figure is computed directly from AURX's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $3M | -76.0% | -75.8% |
| FY2024 | $1M | -180.0% | -170.2% |
| FY2023 | $1M | -520.6% | -521.2% |
| FY2022 | $0M | -2958.2% | -2825.6% |
| FY2021 | $0M | n/a | n/a |
How does AURX compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: A · ACHR · AEHR · AERG · AEVA · AIRI
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.